187 related articles for article (PubMed ID: 12638471)
1. Laboratory Monitoring of Heparin Anticoagulation in Hemodialysis: Rationale and Strategies.
Chiasakul T; Mullier F; Lecompte T; Nguyen P; Cuker A
Semin Nephrol; 2023 Nov; 43(6):151477. PubMed ID: 38290962
[TBL] [Abstract][Full Text] [Related]
2. Unfractionated Heparins, Low-Molecular-Weight Heparins, and Indirect Factor Xa Inhibitors in Plastic and Reconstructive Surgery: An Evidence-Based Review.
Othman S; Bertolaccini CM; Pannucci CJ
Plast Reconstr Surg; 2024 Jun; 153(6):1224e-1231e. PubMed ID: 37189249
[TBL] [Abstract][Full Text] [Related]
3. Low-molecular-weight heparin for the treatment of patients with mechanical heart valves.
Shapira Y; Sagie A; Battler A
Clin Cardiol; 2002 Jul; 25(7):323-7. PubMed ID: 12109865
[TBL] [Abstract][Full Text] [Related]
4. Management of an unintentional enoxaparin overdose: A case report and literature review.
Zhou FN; Gellatly RM
Am J Health Syst Pharm; 2023 Oct; 80(21):1550-1556. PubMed ID: 37522871
[TBL] [Abstract][Full Text] [Related]
5. Glass bead-activated clotting time (gb-ACT) for monitoring the anticoagulation effects in elderly patients with high risk of venous thromboembolism (VTE).
Peng P; Chen Y; Yang G; Qin M; Xu X; Zhou Y
Expert Opin Drug Saf; 2024 May; ():1-8. PubMed ID: 38767877
[TBL] [Abstract][Full Text] [Related]
6. Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route.
Qi Y; Zhao G; Liu D; Shriver Z; Sundaram M; Sengupta S; Venkataraman G; Langer R; Sasisekharan R
Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9867-72. PubMed ID: 15226520
[TBL] [Abstract][Full Text] [Related]
7. Smaller nadroparin dose reductions required for patients with renal impairment: A multicenter cohort study.
van Uden RCAE; Jaspers TCC; Meijer K; van Stralen KJ; Maat B; Khorsand N; van Onzenoort HAW; Swart EL; Huls HJ; Mathôt RAA; Lukens MV; van den Bemt PMLA; Becker ML
Thromb Res; 2024 Apr; 236():4-13. PubMed ID: 38377636
[TBL] [Abstract][Full Text] [Related]
8. Extensive arm skin necrosis following administration of unfractionated heparin.
Firouzabadi D; Petramfar P; Mahmoudi L
Indian J Pharmacol; 2023; 55(5):332-334. PubMed ID: 37929412
[TBL] [Abstract][Full Text] [Related]
9. Current dosing of low-molecular-weight heparins does not reflect licensed product labels: an international survey.
Barras MA; Kirkpatrick CM; Green B
Br J Clin Pharmacol; 2010 May; 69(5):520-8. PubMed ID: 20573088
[TBL] [Abstract][Full Text] [Related]
10. Arterial indications for the low molecular weight heparins.
Ageno W; Huisman MV
Curr Control Trials Cardiovasc Med; 2001; 2(5):233-239. PubMed ID: 11806802
[TBL] [Abstract][Full Text] [Related]
11. Elevated Anti-Xa in the Setting of Prophylactic Unfractionated Subcutaneous Heparin Administration.
Weinstein T; Altshuler D; Lafond E; Katz A
J Pharm Pract; 2024 Jan; ():8971900241228951. PubMed ID: 38237567
[TBL] [Abstract][Full Text] [Related]
12. Immune-stealth VP28-conjugated heparin nanoparticles for enhanced and reversible anticoagulation.
Hussein HR; Chang CY; Zheng Y; Yang CY; Li LH; Lee YT; Chen JY; Liang YC; Lin CJ; Chang YC; Geo HN; Noor SM; Kiew LV; Chen FR; Chang CC
Nanotechnology; 2024 Feb; 35(17):. PubMed ID: 38262054
[TBL] [Abstract][Full Text] [Related]
13. Heparin pharmacokinetics and pharmacodynamics.
Kandrotas RJ
Clin Pharmacokinet; 1992 May; 22(5):359-74. PubMed ID: 1505142
[TBL] [Abstract][Full Text] [Related]
14. Comparison of low-molecular-weight-heparin and unfractionated heparin for acute PTE.
Chen LY; Ying KJ; Hong WJ; Zhou P
J Zhejiang Univ Sci B; 2005 Dec; 6(12):1195-9. PubMed ID: 16358378
[TBL] [Abstract][Full Text] [Related]
15. [Heparins].
Marbet GA
Ther Umsch; 2003 Jan; 60(1):10-3. PubMed ID: 12638471
[TBL] [Abstract][Full Text] [Related]
16. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
17. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Hirsh J; Raschke R
Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
[TBL] [Abstract][Full Text] [Related]
18. The use of unfractionated heparin and low molecular weight heparins in pregnancy.
Casele HL
Clin Obstet Gynecol; 2006 Dec; 49(4):895-905. PubMed ID: 17082684
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
